Cargando…

Comparison of Different Liver Test Thresholds for Drug-Induced Liver Injury: Updated RUCAM versus Other Methods

According to the updated Roussel Uclaf Causality Assessment Method (RUCAM), drug-induced liver injury (DILI) is currently defined based on thresholds of alanine aminotransferase (ALT) levels above 5 × the upper limit of normal (ULN) and/or alkaline phosphatase (ALP) levels greater than 2 × the ULN....

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hongyi, Guo, Daihong, Xu, Yuanjie, Zhu, Man, Yao, Chong, Chen, Chao, Jia, Wangping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658872/
https://www.ncbi.nlm.nih.gov/pubmed/31379581
http://dx.doi.org/10.3389/fphar.2019.00816
_version_ 1783439026603163648
author Yang, Hongyi
Guo, Daihong
Xu, Yuanjie
Zhu, Man
Yao, Chong
Chen, Chao
Jia, Wangping
author_facet Yang, Hongyi
Guo, Daihong
Xu, Yuanjie
Zhu, Man
Yao, Chong
Chen, Chao
Jia, Wangping
author_sort Yang, Hongyi
collection PubMed
description According to the updated Roussel Uclaf Causality Assessment Method (RUCAM), drug-induced liver injury (DILI) is currently defined based on thresholds of alanine aminotransferase (ALT) levels above 5 × the upper limit of normal (ULN) and/or alkaline phosphatase (ALP) levels greater than 2 × the ULN. However, many parameters with different thresholds are also currently used in the clinic. We therefore performed a comparative analysis to evaluate which set of criteria was the most appropriate to detect DILI. We enrolled hospitalized patients who received fluoroquinolones to treat or prevent infections. Three liver test criteria were used to diagnose DILI in these patients. RUCAM criteria were defined as the gold standard, and the other two criteria were as follows: 1) ALT or aspartate aminotransferase (AST) levels greater than 5 × the ULN on two consecutive occasions and/or ALP levels greater than 2 × the ULN on two consecutive occasions [issued by DILI Network (DILIN)]; 2) ALT levels greater than 1 × the ULN on two consecutive occasions or ALT levels greater than 2 × the ULN [issued by the National Medical Products Administration (NMPA) of China]. We found that the RUCAM criteria resulted in 657 warnings, DILIN criteria resulted in 358, NMPA criteria resulted in 1,377, and the positive predictive value (PPV) were 9.74%, 10.89%, and 9.73% (P = 0.80), respectively. The levels of agreement of the DILIN and NMPA criteria with the RUCAM criteria were moderate, but the agreement between the DILIN criteria and NMPA criteria was poor. In conclusion, the NMPA criteria with relatively lax thresholds for the parameters require much more labor to determine the diagnosis, making them unsuitable for clinical practice. Conversely, the DILIN criteria employing stricter thresholds for the parameters were more effective but would miss some positive cases, and the cases it identified were usually quite serious, which is not conductive to early intervention. Therefore, we still recommend the use of the RUCAM criteria in clinical practice.
format Online
Article
Text
id pubmed-6658872
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66588722019-08-02 Comparison of Different Liver Test Thresholds for Drug-Induced Liver Injury: Updated RUCAM versus Other Methods Yang, Hongyi Guo, Daihong Xu, Yuanjie Zhu, Man Yao, Chong Chen, Chao Jia, Wangping Front Pharmacol Pharmacology According to the updated Roussel Uclaf Causality Assessment Method (RUCAM), drug-induced liver injury (DILI) is currently defined based on thresholds of alanine aminotransferase (ALT) levels above 5 × the upper limit of normal (ULN) and/or alkaline phosphatase (ALP) levels greater than 2 × the ULN. However, many parameters with different thresholds are also currently used in the clinic. We therefore performed a comparative analysis to evaluate which set of criteria was the most appropriate to detect DILI. We enrolled hospitalized patients who received fluoroquinolones to treat or prevent infections. Three liver test criteria were used to diagnose DILI in these patients. RUCAM criteria were defined as the gold standard, and the other two criteria were as follows: 1) ALT or aspartate aminotransferase (AST) levels greater than 5 × the ULN on two consecutive occasions and/or ALP levels greater than 2 × the ULN on two consecutive occasions [issued by DILI Network (DILIN)]; 2) ALT levels greater than 1 × the ULN on two consecutive occasions or ALT levels greater than 2 × the ULN [issued by the National Medical Products Administration (NMPA) of China]. We found that the RUCAM criteria resulted in 657 warnings, DILIN criteria resulted in 358, NMPA criteria resulted in 1,377, and the positive predictive value (PPV) were 9.74%, 10.89%, and 9.73% (P = 0.80), respectively. The levels of agreement of the DILIN and NMPA criteria with the RUCAM criteria were moderate, but the agreement between the DILIN criteria and NMPA criteria was poor. In conclusion, the NMPA criteria with relatively lax thresholds for the parameters require much more labor to determine the diagnosis, making them unsuitable for clinical practice. Conversely, the DILIN criteria employing stricter thresholds for the parameters were more effective but would miss some positive cases, and the cases it identified were usually quite serious, which is not conductive to early intervention. Therefore, we still recommend the use of the RUCAM criteria in clinical practice. Frontiers Media S.A. 2019-07-19 /pmc/articles/PMC6658872/ /pubmed/31379581 http://dx.doi.org/10.3389/fphar.2019.00816 Text en Copyright © 2019 Yang, Guo, Xu, Zhu, Yao, Chen and Jia http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yang, Hongyi
Guo, Daihong
Xu, Yuanjie
Zhu, Man
Yao, Chong
Chen, Chao
Jia, Wangping
Comparison of Different Liver Test Thresholds for Drug-Induced Liver Injury: Updated RUCAM versus Other Methods
title Comparison of Different Liver Test Thresholds for Drug-Induced Liver Injury: Updated RUCAM versus Other Methods
title_full Comparison of Different Liver Test Thresholds for Drug-Induced Liver Injury: Updated RUCAM versus Other Methods
title_fullStr Comparison of Different Liver Test Thresholds for Drug-Induced Liver Injury: Updated RUCAM versus Other Methods
title_full_unstemmed Comparison of Different Liver Test Thresholds for Drug-Induced Liver Injury: Updated RUCAM versus Other Methods
title_short Comparison of Different Liver Test Thresholds for Drug-Induced Liver Injury: Updated RUCAM versus Other Methods
title_sort comparison of different liver test thresholds for drug-induced liver injury: updated rucam versus other methods
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658872/
https://www.ncbi.nlm.nih.gov/pubmed/31379581
http://dx.doi.org/10.3389/fphar.2019.00816
work_keys_str_mv AT yanghongyi comparisonofdifferentlivertestthresholdsfordruginducedliverinjuryupdatedrucamversusothermethods
AT guodaihong comparisonofdifferentlivertestthresholdsfordruginducedliverinjuryupdatedrucamversusothermethods
AT xuyuanjie comparisonofdifferentlivertestthresholdsfordruginducedliverinjuryupdatedrucamversusothermethods
AT zhuman comparisonofdifferentlivertestthresholdsfordruginducedliverinjuryupdatedrucamversusothermethods
AT yaochong comparisonofdifferentlivertestthresholdsfordruginducedliverinjuryupdatedrucamversusothermethods
AT chenchao comparisonofdifferentlivertestthresholdsfordruginducedliverinjuryupdatedrucamversusothermethods
AT jiawangping comparisonofdifferentlivertestthresholdsfordruginducedliverinjuryupdatedrucamversusothermethods